What is the difference between Arexvy and Abrysvo?

Official answer

by Drugs.com

Arexvy and Abrysvo are both respiratory syncytial virus (RSV) vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD).

Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age, making it the first RSV vaccine to be FDA-approved for this purpose.

But what are some other differences between them?

Differences in manufacturers and approval dates

Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults.

Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. It was FDA-approved for pregnant women on August 21, 2023.

Differences in efficacy reporting

The way each company reported on their vaccine's efficacy was different which makes a direct comparison difficult.

Arexvy showed 94.6% efficacy in reducing the risk of developing RSV-associated LRTD in older adults with underlying conditions, with an overall efficacy of 82.6%.

Abrysvo showed 67% efficacy in reducing the risk of developing RSV-associated LRTD in older adults with 2 or more symptoms, and 86% efficacy in reducing the risk of developing RSV-associated LRTD in those with 3 or more symptoms. The MATISSE (MATernal Immunization Study for Safety and Efficacy) phase 3 trial reported a vaccine efficacy of 81.8% was observed against severe medically attended LRTD due to RSV in infants from birth through the first 90 days of life with high efficacy of 69.4% demonstrated through the first six months of life.

Warnings

There are no differences in warnings between the 2 products. Neither should be used in people who are hypersensitive to any of the components of either vaccine and neither is approved for use in adults aged less than 60 years or in children. Only Abrysvo is approved for use in pregnancy The following warnings are the same for all vaccines:

Possible anaphylactic reactions

Possible fainting (syncope)

Immunosuppressed people may have a diminished response.

Administration

Both Arexvy and Abrysvo are 0.5ml vaccines that are given by intramuscular injection, preferably into the deltoid muscle of the upper arm.

Side effects

Both vaccines are generally well tolerated and side effects are similar and short-lived.

The most common side effects of Arexvy are injection site pain, fatigue, mild to moderate muscle or joint aches, or headache.

The most common side effects of Abrysvo are fatigue, headache, injection site pain and redness, and muscle pain. In pregnant women, the safety and side-effect profiles of Abrysvo were similar to those seen in previous studies and included pain at the injection site, headache, muscle pain, and nausea. Preeclampsia occurred in 1.8 percent of pregnant individuals who received Abrysvo compared with 1.4 percent of those who received placebo. Low birth weight and jaundice also occurred at a higher rate in infants of pregnant recipients of Abrysvo versus placebo. Prescribing information for pregnant women will include a warning about a "numerical imbalance" in preterm births in Abrysvo recipients: 5.7 percent versus 4.7 percent in those who received placebo but this data is not sufficient enough to establish that the vaccine can cause preterm births, but provides a warning.

Vaccination ingredients

The main difference between Arexvy and Abrysvo is in their composition. Arexvy is an adjuvanted vaccine which means it contains a substance that helps to enhance the effects of the vaccine by boosting the response of the immune system. Abrysvo contains no adjuvant, but it is bivalent, meaning that it protects against both RSV A and RSV B. Although Arexvy is technically not bivalent, trials showed it protected against both the A and B strains of RSV. Both need reconstitution before use.

Natural rubber latex is not used in either vaccine.

The Arexvy vial stopper is not made with natural rubber latex.

The Abrysvo vial stopper, tip cap, and rubber plunger of the prefilled syringe are not made with natural rubber latex.

Arexvy

Arexvy is an adjuvanted RSV vaccine that is supplied in two vials that must be reconstituted before administration. One vial contains lyophilized recombinant respiratory syncytial virus glycoprotein F stabilized in pre-fusion conformation (rsv vaccine pref3, recombinant systemic) as the antigen component, which must be reconstituted at the time of use with the accompanying vial of GSK’s proprietary AS01E adjuvant as the adjuvant suspension component.

After reconstitution, each dose of Arexvy is approximately 0.5 ml and contains:

120 mcg of the recombinant RSVPreF3 antigen, 25 mcg of MPL, and 25 mcg of QS-21.

The following buffer ingredients: 14.7 mg of Trehalose, 4.4 mg of sodium chloride, 0.83 mg of potassium dihydrogen phosphate, 0.26 mg of dipotassium phosphate, 0.18 mg of polysorbate 80, 0.15 mg of disodium phosphate anhydrous, 0.5 mg of DOPC, and 0.125 mg of cholesterol.

Abrysvo

Abrysvo is a bivalent recombinant stabilized prefusion F protein subunit vaccine that contains equal amounts of stabilized prefusion (preF) antigens from the two major RSV subgroups: RSV A and RSV B (rsv vaccine, pref a-pref b, recombinant systemic). It is supplied as a kit that contains a vial of Lyophilized Antigen Component (a sterile white powder), a prefilled syringe containing the sterile water diluent component, and a vial adapter.

After reconstitution, each dose of Abrysvo is approximately 0.5 mL and contains:

120 mcg of RSV stabilized prefusion F proteins (60 mcg RSV preF A and 60 mcg RSV preF B) per 0.5 mL

The following buffer ingredients: 0.11 mg tromethamine, 1.04 mg tromethamine hydrochloride, 11.3 mg sucrose, 22.5 mg mannitol, 0.08 mg polysorbate 80, and 1.1 mg sodium chloride per 0.5 mL.

Abrysvo contains no preservatives and residual amounts of host cell proteins (≤0.1% w/w) and DNA (<0.4 ng/mg of total protein) may be present from the manufacturing process.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.